Lifastuzumab vedotin

Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research[1].

Product Specifications

CAS Number

[1401812-88-1]

Product Name Alternative

RG-7599; DNIB-0600A; NaPi2b-ADC

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Related Pathways

Antibody-drug Conjugate/ADC Related

Field of Research

Cancer

Purity

99.03

Solubility

10 mM in DMSO

Smiles

[Lifastuzumabvedotin]

References & Citations

[1]S Banerjee, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29 (4) :917-923.|[2]David E Gerber, et al. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2020 Jan 15;26 (2) :364-372.